Sei Investments Co. Sells 49,577 Shares of DBV Technologies S.A. $DBVT

Sei Investments Co. decreased its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 74.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,764 shares of the company’s stock after selling 49,577 shares during the quarter. Sei Investments Co.’s holdings in DBV Technologies were worth $350,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Artisan Partners Limited Partnership boosted its stake in shares of DBV Technologies by 6,273.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock valued at $63,435,000 after purchasing an additional 3,257,135 shares in the last quarter. Siren L.L.C. bought a new position in DBV Technologies in the 4th quarter valued at approximately $35,606,000. Vivo Capital LLC lifted its stake in DBV Technologies by 133.4% in the 4th quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock valued at $47,189,000 after purchasing an additional 1,407,120 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new position in DBV Technologies in the 2nd quarter valued at approximately $9,659,000. Finally, MPM Bioimpact LLC acquired a new stake in DBV Technologies in the second quarter valued at approximately $9,649,000. Institutional investors own 71.74% of the company’s stock.

Analysts Set New Price Targets

DBVT has been the subject of several research analyst reports. Guggenheim reiterated a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a report on Monday, May 4th. Weiss Ratings downgraded DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Finally, Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Price Performance

DBVT opened at $14.02 on Monday. DBV Technologies S.A. has a fifty-two week low of $8.70 and a fifty-two week high of $26.18. The company’s 50 day moving average price is $15.21 and its two-hundred day moving average price is $18.70. The firm has a market capitalization of $881.58 million, a price-to-earnings ratio of -3.99 and a beta of -0.93.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The business had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.90 million. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. As a group, equities research analysts predict that DBV Technologies S.A. will post -2.05 EPS for the current year.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.